The United States Anti-Doping Agency (USADA)¬†announced today in a press release that women’s strawweight fighter Amanda Ribas (6-1-0) will serve a two-year suspension for an anti-doping violation in June 2017.

More specifically, an out-of-competition test performed by USADA on June 7, 2017 indicated a positive test for Ostarine. According to the release, “Ostarine, also known as MK-2866 and Enobosarm, is a non-FDA approved selective androgen receptor modulator (SARM) that is illegally sold in the United States and worldwide as a performance-enhancing substance. Ostarine is not currently available as a prescription medication in any country, and its unauthorized use may carry serious side effects.”

The UFC has not yet officially commented on Ribas’ suspension.

Ribas, 24, currently trains with American Top Team. She was recently signed to the UFC but will now debut after June 7, 2019 at the earliest.